Outcome | Oxidative stress marker | Modelling | ncases | Model 1 | Model 2 | Model 3 | Model 4 |
---|---|---|---|---|---|---|---|
RR (95 % CI)a | RR (95 % CI)b | RR (95 % CI)c | RR (95 % CI)d | ||||
All-cause mortality | d-ROMs | ≤340 Carr U | 499 | Ref | Ref | Ref | Ref |
341–400 Carr U | 545 | 1.27 (1.07–1.51)* | 1.21 (1.04–1.40)* | 1.20 (1.03–1.40)* | 1.13 (0.96–1.32) | ||
401–500 Carr U | 499 | 1.86 (1.58–2.17)* | 1.60 (1.35–1.89)* | 1.53 (1.29–1.83)* | 1.32 (1.10–1.59)* | ||
>500 Carr U | 159 | 4.48 (2.87–7.00)* | 3.79 (2.08–6.90)* | 2.99 (1.62–5.52)* | 2.30 (1.40–3.77)* | ||
d-ROMs | Increase per 1 SDe | 1702 | 1.44 (1.35–1.53)* | 1.34 (1.25–1.43)* | 1.28 (1.19–1.36)* | 1.20 (1.12–1.29)* | |
TTL | Decrease per 1 SDf | 1702 | 1.17 (1.04–1.33)* | 1.19 (1.07–1.32)* | 1.14 (1.06–1.23)* | 1.12 (1.04–1.21)* | |
CVD mortality | d-ROMs | ≤340 Carr U | 157 | Ref | Ref | Ref | Ref |
341–400 Carr U | 178 | 1.29 (1.00–1.67)* | 1.28 (0.97–1.70) | 1.28 (0.89–1.82) | 1.14 (0.83–1.56) | ||
401–500 Carr U | 171 | 1.71 (1.32–2.22)* | 1.78 (1.31–2.43)* | 1.81 (1.28–2.54)* | 1.49 (1.04–2.13)* | ||
>500 Carr Ug | 54 | 5.16 (2.35–11.31)* | 5.09 (2.67–9.69)* | 4.86 (2.38–9.95)* | 4.34 (2.06–9.15)* | ||
d-ROMs | Increase per 1 SDe | 560 | 1.53 (1.35–1.72)* | 1.44 (1.27–1.64)* | 1.37 (1.19–1.58)* | 1.30 (1.12–1.51)* | |
TTL | Decrease per 1 SDf | 560 | 1.31 (1.17–1.47)* | 1.30 (1.15–1.48)* | 1.27 (1.10–1.47)* | 1.25 (1.09–1.45)* | |
Cancer mortality | d-ROMs | ≤340 Carr U | 198 | Ref | Ref | Ref | Ref |
341–400 Carr U | 224 | 1.27 (1.01–1.61)* | 1.18 (0.92–1.51) | 1.17 (0.91–1.52) | 1.08 (0.83–1.41) | ||
401–500 Carr U | 200 | 1.71 (1.32–2.21)* | 1.48 (1.12–2.75)* | 1.41 (1.05–1.89)* | 1.16 (0.85–1.57) | ||
>500 Carr U | 80 | 5.29 (3.16–8.85)* | 4.34 (2.31–8.16)* | 3.82 (1.79–8.18)* | 2.50 (1.31–4.78)* | ||
d-ROMs | Increase per 1 SDe | 702 | 1.42 (1.29–1.56)* | 1.35 (1.20–1.52)* | 1.30 (1.14–1.47)* | 1.19 (1.05–1.35)* | |
TTL | Decrease per 1 SDf | 702 | 1.05 (0.92–1.19) | 1.07 (0.96–1.19) | 1.01 (0.90–1.13) | 0.98 (0.87–1.09) | |
Non-CVD, non-cancer mortality | d-ROMs | ≤340 Carr U | 103 | Ref | Ref | Ref | Ref |
341–400 Carr U | 99 | 1.15 (0.80–1.67) | 0.94 (0.52–1.68) | 0.97 (0.51–1.82) | 0.85 (0.48–1.49) | ||
401–500 Carr U | 99 | 2.14 (1.51–3.05)* | 1.49 (0.91–2.45) | 1.51 (0.89–2.55) | 1.16 (0.67–2.01) | ||
>500 Carr U | 21 | 3.32 (1.68–6.59)* | 1.98 (0.94–4.15) | 1.93 (0.83–4.45) | 1.56 (0.69–3.53) | ||
d-ROMs | Increase per 1 SDe | 322 | 1.41 (1.22–1.63)* | 1.26 (1.08–1.47)* | 1.27 (1.07–1.51)* | 1.15 (0.96–1.37) | |
TTL | Decrease per 1 SDf | 322 | 1.23 (1.07–1.42)* | 1.27 (1.02–1.60)* | 1.19 (0.94–1.48) | 1.15 (0.93–1.43) |